WallStSmart

Abbott Laboratories (ABT)vsElectromed Inc (ELMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 64273% more annual revenue ($44.33B vs $68.86M). ABT leads profitability with a 14.7% profit margin vs 13.1%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 68/100 (B-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

ELMD

Strong Buy

68

out of 100

Grade: B-

Growth: 8.7Profit: 7.5Value: 10.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
ELMDUndervalued (+47.6%)

Margin of Safety

+47.6%

Fair Value

$48.20

Current Price

$24.66

$23.54 discount

UndervaluedFair: $48.20Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

ELMD4 strengths · Avg: 8.8/10
PEG RatioValuation
0.3510/10

Growing faster than its price suggests

Return on EquityProfitability
20.2%9/10

Every $100 of equity generates 20 in profit

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

EPS GrowthGrowth
45.5%8/10

Earnings expanding 45.5% YoY

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ELMD1 concerns · Avg: 3.0/10
Market CapQuality
$194.17M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : ELMD

The strongest argument for ELMD centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 16.3% demonstrates continued momentum. PEG of 0.35 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : ELMD

The primary concerns for ELMD are Market Cap.

Key Dynamics to Monitor

ABT profiles as a value stock while ELMD is a growth play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.74 — expect wider price swings.

ELMD is growing revenue faster at 16.3% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ELMD scores higher overall (68/100 vs 51/100) and 16.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Electromed Inc

HEALTHCARE · MEDICAL DEVICES · USA

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.

Want to dig deeper into these stocks?